Bevacizumab beyond progression in breast cancer

Affiliations

¹ Medical Oncology, Sint-Augustinus-University of Antwerp, Antwerp 2610, Belgium. Electronic address: luc.dirix@telenet.be.
² The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

Comment

Luc Y Dirix et al. Lancet Oncol. 2014 Oct.

. 2014 Oct;15(11):1190-1.

doi: 10.1016/S1470-2045(14)70454-1. Epub 2014 Sep 28.

¹ Medical Oncology, Sint-Augustinus-University of Antwerp, Antwerp 2610, Belgium. Electronic address: luc.dirix@telenet.be.
² The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

No abstract available

Comment on

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. von Minckwitz G, et al. Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28. Lancet Oncol. 2014. PMID: 25273342 Clinical Trial.